{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:08:57Z","timestamp":1779091737369,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Infusion-related reactions (IRRs) are a common side-effect of ocrelizumab (OCR), with the highest risk occurring during treatment initiation. To minimize IRR risk, the first dose is split into two 300\u2005mg infusions over two weeks. Subsequent doses are administered every six months as a 600\u2005mg infusion. After treatment interruptions, some physicians restart with two separate 300\u2005mg infusions due to concern about IRRs. This study evaluates IRR occurrence following a 600\u2005mg infusion after extended treatment interruption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included all multiple sclerosis (MS) patients who received at least one 600\u2005mg OCR infusion between June 2018 and January 2024 at Amsterdam UMC. Infusions were categorized by interval duration: normal (6 months), moderate (7\u20139 months) and long (&gt;9 months). Logistic regression analyzed the IRR occurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      1438 infusions, in 275 patients, were analyzed. Neither the moderate interval group (306 infusions, OR = 0.914,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.77) nor the long interval group (56 infusions, OR = 0.928,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.575) had significantly higher odds of developing IRRs compared to the normal interval group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the retrospective design and smaller sample sizes in the moderate and long interval groups, our findings indicate that administering OCR as a single 600\u2005mg infusion after a prolonged interval is safe regarding IRR occurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20552173261449688","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:50:36Z","timestamp":1778849436000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reinitiating ocrelizumab with a full 600\u2005mg dose after extended treatment interruption: No increased risk of infusion-related reactions"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9845-5031","authenticated-orcid":false,"given":"Lisa G","family":"Schoof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1230-1366","authenticated-orcid":false,"given":"Laura","family":"Hogenboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-5381","authenticated-orcid":false,"given":"Zo\u00e9 LE","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob W","family":"van Oosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-5864","authenticated-orcid":false,"given":"Eva MM","family":"Strijbis","sequence":"additional","affiliation":[{"name":"Amsterdam UMC location VUmc"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11943-4"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12326-z"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000807"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012700"},{"key":"e_1_3_3_6_2","unstructured":"ROCHE. Restarting ocrevus after a prolonged interruption of therapy https:\/\/medically.roche.com\/global\/en\/medinfo\/ocrevus\/restarting-ocrevus-after-a-prolonged-interruption-of-therapy.html (accessed 06-03-2025 2025)."},{"key":"e_1_3_3_7_2","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf (2017 accessed 1 November 2022)."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.044"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102279"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241245296"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214917"},{"key":"e_1_3_3_12_2","unstructured":"Svenningsson A Frisell T Burman J et al. Rituximab long-term DOSE trial in Multiple Sclerosis-RIDOSE-MS: A phase 3 trial investigating extended dosing regimen of rituximab in relapsing-remitting MS. Presented at ECTRIMS 2025 abstract O131. 2025."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102454"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01999-x"},{"key":"e_1_3_3_15_2","first-page":"20240419","article-title":"Comparing the risk of infusion-related reactions and tolerability in patients given cetirizine or diphenhydramine prior to ocrelizumab infusion (PRECEPT)","volume":"60","author":"Smoot K","year":"2024","unstructured":"Smoot K, Marginean H, Gervasi-Follmar T, et al. Comparing the risk of infusion-related reactions and tolerability in patients given cetirizine or diphenhydramine prior to ocrelizumab infusion (PRECEPT). Medicina (Kaunas) 2024; 60: 20240419.","journal-title":"Medicina (Kaunas)"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"De Seze J Hauser SL Kappos L et al. Infusion-related reactions with ocrelizumab in phase III studies. EP1671. ECTRIMS. Paris France 199691. 2017.","DOI":"10.26226\/morressier.59a3e8b6d462b8028d8950ee"}],"container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173261449688","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552173261449688","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173261449688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:47:12Z","timestamp":1779090432000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552173261449688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/20552173261449688"],"URL":"https:\/\/doi.org\/10.1177\/20552173261449688","relation":{},"ISSN":["2055-2173","2055-2173"],"issn-type":[{"value":"2055-2173","type":"print"},{"value":"2055-2173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"20552173261449688"}}